NEW CV
INDICATION 1 †
Only Wegovy ® provides transformative weight loss and protects the heart 1 – 4 †
†Wegovy ® is indicated for weight management in adults and adolescents , and for reduction in risk of CV events in adults with a BMI of ≥27 kg / m 2 and established CVD . 1
WEIGHT LOSS Achieved by ~ 1 in 3 patients treated over 68 weeks 1 – 3 #
REDUCTION IN MACE
vs placebo on top of CV standard of care in adults with established CVD 1 , 4^
4-YEAR SAFETY PROFILE CONSISTENT WITH THE GLP-1 RA CLASS 1 , 5 ‡
For more information about Wegovy ® 2.4 mg , including practical resources , upcoming educational events and the wegovycare ® patient support program , scan the QR code or visit wegovy . com . au
#
STEP 1 and 4 : Mean weight loss of 15 – 17 % ( p < 0.001 vs placebo ) as an adjunct to a reduced-energy diet and increased physical activity in patients with a BMI of ≥27 kg / m 2 in the presence of at least one weight-related comorbidity or a BMI of ≥30 kg / m 2 regardless of a comorbidity ; 30.2 % of patients in STEP 1 and 38.6 % of patients in STEP 4 achieved ≥20 % weight loss with Wegovy ® ; supportive secondary endpoint , p-value not available , not to be used to infer definitive treatment effect . Mean baseline body weight and BMI of 105 – 107 kg and 37.9 – 38.4 kg / m 2 , respectively . 1 – 3 ^SELECT : First occurrence of MACE ( CV death , non-fatal myocardial infarction or non-fatal stroke ) vs placebo to manage CV risk factors in adults with a BMI ≥27 kg / m 2 and established CVD ( HR 0.80 , 95 % CI 0.72 – 0.90 , p < 0.001 ). 1 , 4 ‡ The overall safety profile in SELECT at 4 years did not reveal any new safety signals from prior STEP studies . 5 The most common side effects associated with Wegovy ® 2.4 mg in the STEP trials were gastrointestinal ( nausea = 38 %, diarrhoea = 27 %, constipation = 22 %, vomiting = 22 %, abdominal pain = 18 %), headache ( 13 %) and fatigue ( 10 %). 1 Gastrointestinal adverse events were predominately of mild-to-moderate severity and subsided over time . 1 – 3 Across four 68-week phase III clinical trials of 2,650 adults who received Wegovy ® 2.4 mg , acute pancreatitis was reported in 0.2 % of patients . If suspected , Wegovy ® should be discontinued and only restarted once pancreatitis is ruled out . 1
This medicinal product is subject to additional monitoring in Australia . This will allow quick identifi cation of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems .
PBS Information : This product is not listed on the PBS .
Please review full Product Information before prescribing , available at https :// rss . medsinfo . com . au / no / pi . cfm ? product = nopwegov
Scan QR code to see full Wegovy ® ( semaglutide 2.4 mg ) Product Information
BMI : body mass index ; CI : confidence interval ; CV : cardiovascular ; CVD : cardiovascular disease ; GLP-1 RA : glucagon-like peptide-1 receptor agonist ; HR : hazard ratio ; MACE : major adverse cardiovascular event .
References : 1 . Wegovy ® ( semaglutide 2.4 mg ) Approved Product Information . Available at : https :// rss . medsinfo . com . au / no / pi . cfm ? product = nopwegov . 2 . Wilding JPH , et al . N Engl J Med . 2021 ; 384:989 – 1002 ( plus supplementary appendix ). 3 . Rubino D , et al . JAMA . 2021 ; 325:1414 – 25 ( plus supplementary appendix ). 4 . Lincoff AM , et al . N Engl J Med . 2023 ; 389:2221 – 32 . 5 . Ryan DH , et al . Nat Med . 2024 ; 30:2049 – 57 .
Novo Nordisk Pharmaceuticals Pty Ltd . Level 10 , 118 Mount Street , North Sydney NSW 2060 . ABN 40 002 879 996 . Novo Nordisk ® Medical Information ( Australia ) 1800 668 626 . www . novonordisk . com . au . ® Registered trademark of Novo Nordisk A / S . NOOBOY0283 . AU24SEMO00314 . January 2025 .